A Study of VIRTUGUIDE System and DePuy Synthes Lapidus Implant in Participants Undergoing Lapidus Procedure

ConditionHallux Valgus
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age22+
SponsorDePuy Synthes Products, Inc.

About this trial

The purpose of this study is to assess the surgeon experience and surgery outcomes in participants undergoing index Lapidus procedure for the correction of hallux valgus (a foot deformity where the big toe angles outward towards the other toes, causing a painful bony bump at the base of the big toe joint) using the VIRTUGUIDE System and compatible DePuy Synthes Lapidus implants.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Participants, both male and female, >= 22 years old at the time of consent

Participants undergoing a primary Lapidus procedure for the correction of hallux valgus using the VIRTUGUIDE System (software + instruments) and who receive a compatible DePuy Synthes Lapidus implant

Participants must be able to read and understand questions and responses in an available translated language for patient reported outcomes (PROMs)

All primary Lapidus fixation implants are used on-label according to the implant IFU/FDA cleared labeling

Disqualifiers

Participation in any other medical device or medicinal product study within the previous month. Participation in observational studies is allowed

In the opinion of the Principal Investigator, the subject is unable to comply with the requirements of the registry

Participant has known allergies to implant components

Participant presenting for a revision of a Lapidus procedure

Trial population

The study population will include adults who will undergo surgical treatment for the correction of hallux valgus via Lapidus procedure using the VIRTUGUIDE System and will receive a compatible DePuy Synthes Lapidus implant.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

100 Participants
are grouped into 1 trial group
Group A: VIRTUGUIDE System and Compatible DePuy Synthes Lapidus Implant(s)

Trial outcomes

Primary outcomes

1

Radiographic Documentation of Fusion/Healing Status

Evaluation of healing, that is, healing will be a combination of radiographic and clinical assessment. Healing (fusion) will be considered achieved based on surgeon interpretation of radiographic images, lack of clinical motion and no pain at the fused site indicative of failed fusion. Imaging, whether X-ray or computed tomography (CT) collected per standard of care (SOC), utilized for radiographic assessment will be collected.

Time frame
Up to 12 months post-procedure
2

Patient Reported Outcome Measures (PROM): Manchester Oxford Foot Questionnaire (Quality of Life Index) Scores

The Manchester Oxford Foot Questionnaire (MOxFQ) with three domains (walking/standing, pain, and social interaction) is a standardized instrument developed and validated specifically for hallux valgus (bunions) corrective surgery. It is widely regarded as the gold standard for content and construct validity. It is designed for self (participant) completion and consists of sixteen (16) questions all of which are scored on a five (5) item Likert scale. The scores for each domain range from 0-100, with 100 representing the worst condition.

Time frame
Up to 12 months post-procedure
3

PROM: Numeric Pain Rating Scale Scores

The Numeric Pain Rating Scale is a three (3) question self-administered PROM with a 10-point one-dimensional line anchored on either end by verbal descriptors ranging from "no pain" to "worst imaginable pain". The higher score indicates greater pain intensity. The three questions ask the participant to indicate the intensity of current, best, and worst pain levels over the past 24 hours.

Time frame
Up to 12 months post-procedure
4

Number of Participants Reporting any Perioperative Adverse Event (AE)

An AE is any untoward medical occurrence (sign, symptom, or disease) in a participant that is deemed at least possibly related to the DePuy Synthes registry device, or any adjunctive implant device used during the index procedure.

Time frame
Up to 12 months post-procedure

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.